Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis

Ayalew Tefferi; Terra L. Lasho; Curtis A. Hanson; Rhett P. Ketterling; Naseema Gangat; Animesh D Pardanani

doi:10.1111/bjh.15010

Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis

Ayalew Tefferi, Terra L. Lasho, Curtis A. Hanson, Rhett P. Ketterling, Naseema Gangat, Animesh D Pardanani

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Journal	British Journal of Haematology
DOIs	https://doi.org/10.1111/bjh.15010
State	Accepted/In press - Jan 1 2017

Keywords

Allogeneic
Primary myelofibrosis
Prognosis
Survival
Transplant

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/bjh.15010

Cite this

@article{69587aa029874679afd3bf6886b534c1,

title = "Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis",

keywords = "Allogeneic, Primary myelofibrosis, Prognosis, Survival, Transplant",

author = "Ayalew Tefferi and Lasho, {Terra L.} and Hanson, {Curtis A.} and Ketterling, {Rhett P.} and Naseema Gangat and Pardanani, {Animesh D}",

year = "2017",

month = jan,

day = "1",

doi = "10.1111/bjh.15010",

language = "English (US)",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis

AU - Tefferi, Ayalew

AU - Lasho, Terra L.

AU - Hanson, Curtis A.

AU - Ketterling, Rhett P.

AU - Gangat, Naseema

AU - Pardanani, Animesh D

PY - 2017/1/1

Y1 - 2017/1/1

KW - Allogeneic

KW - Primary myelofibrosis

KW - Prognosis

KW - Survival

KW - Transplant

UR - http://www.scopus.com/inward/record.url?scp=85034988932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034988932&partnerID=8YFLogxK

U2 - 10.1111/bjh.15010

DO - 10.1111/bjh.15010

M3 - Article

C2 - 29171022

AN - SCOPUS:85034988932

SN - 0007-1048

JO - British Journal of Haematology

JF - British Journal of Haematology

ER -

Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this